Cargando…

Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study

β-thalassemia, a hereditary blood disorder caused by defective synthesis of hemoglobin β globin chains, leads to ineffective erythropoiesis and chronic anemia that may require blood transfusions. Sotatercept (ACE-011) acts as a ligand trap to inhibit negative regulators of late-stage erythropoiesis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cappellini, Maria Domenica, Porter, John, Origa, Raffaella, Forni, Gian Luca, Voskaridou, Ersi, Galactéros, Frédéric, Taher, Ali T., Arlet, Jean-Benoît, Ribeil, Jean-Antoine, Garbowski, Maciej, Graziadei, Giovanna, Brouzes, Chantal, Semeraro, Michaela, Laadem, Abderrahmane, Miteva, Dimana, Zou, Jun, Sung, Victoria, Zinger, Tatiana, Attie, Kenneth M., Hermine, Olivier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395345/ https://www.ncbi.nlm.nih.gov/pubmed/30337358 http://dx.doi.org/10.3324/haematol.2018.198887

Ejemplares similares

Sotatercept in patients with osteolytic lesions of multiple myeloma
por: Abdulkadyrov, Kudrat M, et al.
Publicado: (2014)

Novel Therapeutic Advances in β-Thalassemia
por: Makis, Alexandros, et al.
Publicado: (2021)

Ineffective Erythropoiesis in β-Thalassemia
por: Ribeil, Jean-Antoine, et al.
Publicado: (2013)

Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia
por: Piga, Antonio, et al.
Publicado: (2022)

Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification
por: Coyne, Daniel W., et al.
Publicado: (2019)

Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies
por: Raftopoulos, Haralambos, et al.
Publicado: (2015)

Validation of a patient‐reported outcomes symptom measure for patients with nontransfusion‐dependent thalassemia (NTDT‐PRO(©))
por: Taher, Ali, et al.
Publicado: (2018)

Tricuspid-valve regurgitant jet velocity as a risk factor for death in β-thalassemia
por: Derchi, Giorgio, et al.
Publicado: (2022)

Right in time: Mitapivat for the treatment of anemia in α- and β-thalassemia
por: Musallam, Khaled M., et al.
Publicado: (2022)

Development of a patient‐reported outcomes symptom measure for patients with nontransfusion‐dependent thalassemia (NTDT‐PRO(©))
por: Taher, Ali, et al.
Publicado: (2018)

Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension
por: Joshi, Sachindra R., et al.
Publicado: (2022)

Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension
por: Humbert, Marc, et al.
Publicado: (2023)

Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial
por: Souza, Rogerio, et al.
Publicado: (2023)

β-Thalassemia: New Therapeutic Modalities, Genetics, Complications, and Quality of Life
por: Karimi, Mehran, et al.
Publicado: (2012)

Selecting β-thalassemia Patients for Gene Therapy: A Decision-making Algorithm
por: Baronciani, Donatella, et al.
Publicado: (2021)

Outcomes of Pregnancy in Sickle Cell Disease Patients: Results from the Prospective ESCORT-HU Cohort Study
por: Habibi, Anoosha, et al.
Publicado: (2023)

Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure
por: Joshi, Sachindra R., et al.
Publicado: (2023)

Sotatercept for the treatment of pulmonary arterial hypertension: a meta-analysis of randomized controlled trials
por: Jaiswal, Vikash, et al.
Publicado: (2023)

Case Report of Myelodysplastic Syndrome in a Sickle-Cell Disease Patient Treated with Hydroxyurea and Literature Review
por: Flevari, Pagona, et al.
Publicado: (2022)

Development of a High-Resolution Melting Approach for Scanning Beta Globin Gene Point Mutations in the Greek and Other Mediterranean Populations
por: Chassanidis, Christos, et al.
Publicado: (2016)

Pharmacological Induction of Fetal Hemoglobin in β-Thalassemia and Sickle Cell Disease: An Updated Perspective
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2022)

Luspatercept for transfusion-dependent β-thalassemia: time to get real
por: Musallam, Khaled M., et al.
Publicado: (2023)

Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia
por: Taher, Ali T, et al.
Publicado: (2023)

Redox Balance in β-Thalassemia and Sickle Cell Disease: A Love and Hate Relationship
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2022)

P1518: LONG-TERM SAFETY RESULTS OF THE BELIEVE STUDY OF LUSPATERCEPT IN ADULTS WITH ΒETA-THALASSEMIA
por: Viprakasit, V., et al.
Publicado: (2022)

Idiopathic pulmonary fibrosis: Addressing the current and future therapeutic advances along with the role of Sotatercept in the management of pulmonary hypertension
por: Hadi, Dalia D., et al.
Publicado: (2023)

Development of interactive algorithm for clinical management of acute events related to sickle cell disease in emergency department
por: Forni, Gian Luca, et al.
Publicado: (2014)

Untreated Anemia in Nontransfusion-dependent β-thalassemia: Time to Sound the Alarm
por: Musallam, Khaled M., et al.
Publicado: (2022)

Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy
por: Musallam, Khaled M, et al.
Publicado: (2023)

Update on the use of deferasirox in the management of iron overload
por: Taher, Ali, et al.
Publicado: (2009)

CYP450 Mediates Reactive Oxygen Species Production in a Mouse Model of β-Thalassemia through an Increase in 20-HETE Activity
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2021)

Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene
por: Negre, Olivier, et al.
Publicado: (2016)

Low-dose Synachten test with measurement of salivary cortisol in adult patients with β-thalassemia major
por: Ambrogio, Alberto G., et al.
Publicado: (2018)

S273: LONG-TERM ERYTHROID RESPONSE DATA FROM PATIENTS (PTS) WITH NON-TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA (NTDT) RECEIVING LUSPATERCEPT IN THE BEYOND TRIAL
por: Taher, Ali T., et al.
Publicado: (2023)

Population Pharmacokinetics and Exposure‐Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β‐Thalassemia
por: Chen, Nianhang, et al.
Publicado: (2020)

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
por: Taher, Ali T, et al.
Publicado: (2014)

Real‐world complication burden and disease management paradigms in transfusion‐related β‐thalassaemia in Greece: Results from ULYSSES, an epidemiological, multicentre, retrospective cross‐sectional study
por: Kattamis, Antonis, et al.
Publicado: (2023)

P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG?
por: F., GALACTÉROS, et al.
Publicado: (2022)

Primary Hyperparathyroidism in Sickle Cell Disease: An Unknown Complication of the Disease in Adulthood
por: Denoix, Elsa, et al.
Publicado: (2020)

Detection of the sickle hemoglobin allele using a surface plasmon resonance based biosensor
por: Breveglieri, Giulia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_15dl9o8bcc9848su4e7fk0mdqj